Targeted Protein Degradation Market to Hit USD 2,216.13 million by 2032 as PROTAC & Molecular Glue Innovation Accelerates

Targeted Protein Degradation Market Report Scope & Overview

The Targeted Protein Degradation Market continues its strong upward growth as the global valuation surges from USD 540.23 million in 2024 to USD 2,216.13 million by 2032, advancing at a noteworthy CAGR of 19.32% (2025–2032). This exponential trajectory is driven by the unparalleled ability of PROTACs and molecular glues to degrade previously “undruggable” proteins, unlocking new therapeutic pathways across oncology, neurology, and immunology.

The market’s innovation is propelled by rapid advancements in degrader design, integration of AI-based drug discovery, increasing biomarker-driven clinical trials, and a growing shift toward personalized medicine. Robust R&D investments and strategic collaborations among global biotech and pharmaceutical leaders continue to reinforce the strong momentum within the Targeted Protein Degradation Market.

In March 2025, Arvinas expanded its oncology-focused degrader portfolio by advancing ARV-471 and ARV-766 into new clinical stages—marking a critical milestone reflecting the accelerating adoption of TPD strategies worldwide.

Get Ahead of Market Shifts: Request Your Sample Report: https://www.snsinsider.com/sample-request/8436

Expanding R&D Unlocks New Market Potential as Interest in “Undruggable” Proteins Intensifies

The market is rapidly expanding into challenging targets such as transcription factors and disease-specific misfolded proteins. This shift is reshaping drug discovery models and enabling therapeutic breakthroughs in cancer, neurodegeneration, and autoimmune conditions. AI platforms and computational modeling now power high-throughput degrader screening, significantly reducing development timelines.

Moreover, next-generation delivery technologies—including nanoparticles, oral degraders, and antibody-conjugated degraders—are transforming clinical feasibility and improving patient compliance.

U.S. Dominates Global Market With High Innovation Intensity and Strong Clinical Pipelines

The U.S. accounted for USD 212.57 million in 2024, projected to reach USD 861.45 million by 2032 at a CAGR of 19.14%, making it the largest global contributor.

Companies such as Arvinas, Kymera, Nurix, and BMS are pioneering oncology PROTACs and molecular glues, advancing multiple candidates into mid- to late-stage clinical trials. With robust IP protection, world-leading clinical trial infrastructure, and government-funded biotech innovation, the U.S. continues to shape the strategic direction of the Targeted Protein Degradation Market.

Growth Driver: Expansion Into Non-Oncology Indications Unlocks Multi-Billion-Dollar New Opportunities

While oncology remains the largest segment, rapid expansion into neurological, immunological, and infectious diseases is a major catalyst.

In June 2024, nearly 20% of all global TPD candidates targeted neurological and immunological disorders—highlighting the widening therapeutic potential.

Breakthrough developments such as brain-penetrant PROTACs are paving the way for next-generation treatments for Alzheimer’s, Parkinson’s, and ALS.

Market Restraint: Complex Drug Design Slows Early-Stage Development

Despite its immense potential, the development of PROTACs and molecular glues is highly complex. Challenges include:

• Precise E3 ligase selection
• Linker optimization
• Structural stability
• High preclinical failure rates

These hurdles increase R&D costs and development timelines, limiting rapid commercialization across emerging biotech ecosystems.

Market Opportunity: Personalized Protein Degradation Therapies Gain Momentum

The rise of precision medicine is creating a high-value opportunity for patient-specific degraders. With over 160 TPD candidates in clinical development and 40+ in Phase II/III trials (Oct 2024), regulatory acceptance is increasing across global markets. Personalized degraders targeting disease-driving proteins promise higher therapeutic efficacy and reduced adverse effects—positioning this approach as the future of molecular medicine.

Oncology Dominates With 61.38% Share, While Neurological Disorders Lead Future Growth Potential

Oncology accounted for the largest revenue share in 2024 thanks to strong clinical pipelines, high R&D investments, and expanding collaborations.

However, neurological disorders are set to grow at the fastest CAGR of 20.87% due to rapid adoption of brain-targeting PROTACs and molecular glues.

Therapy Development Remains the Core Application, While Drug Discovery Accelerates at 19.75% CAGR

Therapy development held 57.57% of the market in 2024, shaped by the surge in clinical trials and rising demand for first-in-class degraders.

Drug discovery, supported by AI algorithms and high-throughput screening, is expected to expand most rapidly as new degrader targets emerge.

PROTACs Lead With 48.98% Market Share; Molecular Glues Show Explosive 19.98% CAGR

PROTACs dominate thanks to their catalytic degradation, broad disease applicability, and strong patent portfolios.

Molecular glues are expanding faster due to their ability to modulate protein–protein interactions and access difficult targets, fueling rapid R&D momentum.

Pharma & Biotech Companies Hold Highest Share, While Hospitals & Labs Grow Fastest

Pharmaceutical & biotechnology companies lead the market with 40.80% share, backed by extensive pipelines, high R&D budgets, and strategic co-development deals.

Hospital & clinical laboratories are projected to grow fastest at 20.30% CAGR, driven by expanding diagnostic use and increasing clinical trial participation.

Interest in Market Trends: Get Detailed Analysis and Insights with Our Comprehensive Report: https://www.snsinsider.com/reports/targeted-protein-degradation-market-8436

Regional Outlook: Asia-Pacific, North America & Europe Fuel Global Expansion

Asia-Pacific

APAC is emerging as a powerful growth engine, supported by strong biotech investments, rising disease burden, competitive manufacturing, and expanding clinical research hubs in China, Japan, and South Korea.

North America

North America contributed 46.72% of total revenue in 2024, driven by innovation leadership, strong regulatory environments, and extensive pipeline activity.

Europe

Europe is expected to grow at 20.04% CAGR, supported by research excellence, high adoption of personalized medicine, government incentivization, and strong biotech clusters across Germany, the U.K., and Switzerland.

LATAM & MEA

Regions are developing steadily due to improved healthcare infrastructure, rising pharma partnerships, and unmet needs in oncology and chronic diseases.

Competitive Landscape Highlights

Catalent

Expanded biologics and degrader manufacturing capabilities in 2025, supporting 25+ global TPD programs.

Recipharm

Entered strategic partnerships to support commercial-scale TPD production for 10+ candidates.

PCI Pharma

Enhanced specialized packaging and manufacturing services for early- and late-stage degraders to speed commercialization.

Key TPD market players include:

Arvinas, Kymera Therapeutics, Nurix Therapeutics, Foghorn Therapeutics, Vividion, BMS, Novartis, Pfizer, Amgen, Astellas, Merck, Roche, Sanofi, GSK, Evotec, Monte Rosa, Kyowa Kirin, Arrowhead Pharmaceuticals, and more.

Other Trending Reports

Orthopedic Prosthetic Device Market

Aptamers Market

Pediatric Interventional Cardiology Market

Annuloplasty System Market